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PANEL ANALYSIS OF CENSORED MEDICAL COST DATA
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1The MEDSTAT Group, Ann Arbor, MI, USA; 2Michigan State
University, East Lansing, MI, USA
OBJECTIVES: This paper applies the inverse probability
weighted (IPW) least-squares method to estimate the effects of
treatment on total medical cost, subject to censoring, in a panel-
data setting. Two analyses were performed to examine how
patient-and treatment related variables explain total medical
costs for older persons newly diagnosed with lung cancer.
METHODS: IPW pooled ordinary-least squares (POLS) and
IPW random effects (RE) models are used. Because total medical
cost might not be independent of survival time under adminis-
trative censoring, unweighted POLS and RE can not be used with
censored data, to assess the effects of certain explanatory vari-
ables. Even under the violation of this independency IPW esti-
mation gives consistent asymptotic normal coefﬁcients with
easily computable standard errors. A traditional and robust form
of the Hausman test can be used to compare weighted and
unweighted least squares estimators. RESULTS: The methods are
applied to a sample of 201 Medicare beneﬁciaries diagnosed with
lung cancer between 1994 and 1997. Regional stage decreased
total cost of care almost 68% according to IPW POLS and 41%
according to IPW RE compared to in situ or local stage cancer.
A person who received radiation only decreased the total medical
cost relative to mean cost for surgery plus adjuvant therapies.
The estimates with respect to IPW POLS and IPW RE are 72%
and 49%. The Hausman Tests, in comparison between POLS
and IPW POLS, RE and IPW RE models suggest that there exist
no bias due to censoring. CONCLUSION: Measurement of
treatment cost is especially important in the evaluation of
medical intervention, in the analysis of clinical trials and in social
experiment. Currently, statistical methods that are applicable to
administrative data-which is often censored- are under devel-
oped. We offered a model which solves possible selection bias
due to censoring.
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The Costs of Adjuvant Chemotherapy in Early Stage Breast
Cancer Patients: Comparison of Attributable Cost and Micro-
costing Approaches. Objective: To evaluate and compare the
costs of adjuvant chemotherapy in early stage breast cancer
patients utilizing attributable cost and microcosting approaches.
METHODS: For the microcosting analysis, we determined uti-
lization based on clinical guidelines using adriamycin and
cyclophosphamide as adjuvant chemotherapy. Resource prices
were based on reimbursements for drugs and procedures from
Regence Blue Shield, a managed-care organization in the Paciﬁc
Northwest. The attributable cost approach estimates cancer-
related costs as the difference between total costs of female breast
cancer patients and costs of age- and gender-matched control
subjects without breast cancer. Attributable costs were derived
using the Kaplan-Meier Sample Average Estimator. Breast cancer
cases were identiﬁed from a linked database of Regence Blue
Shield claims records and the Surveillance, Epidemiology and
End Results (SEER) cancer registry for Western Washington
State. We hypothesized that attributable costs would be higher
than microcosting because it more extensively accounts for treat-
ment of chemotherapy-associated complications. RESULTS: We
identiﬁed 1356 breast cancer cases for the analysis. Utilizing the
microcosting approach, we estimated that adjuvant chemother-
apy costs, including costs of chemotherapy and anti-nausea
agents and surgical, laboratory and other procedures, were
approximately $4013. Attributable costs of adjuvant chemother-
apy were estimated to be $5330 in preliminary analyses. CON-
CLUSIONS: The integration of managed care claims data with
clinical data from the SEER registry offers a unique opportunity
to derive potentially more accurate disease burden costs in oncol-
ogy. The results of our study will be useful for better under-
standing the differences between costing methods, informing
cost-effectiveness models in breast cancer and evaluating the eco-
nomic burden of the disease.
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AN ACTUARIAL APPROACH TO ESTIMATING THE STREAM OF
COSTS ASSOCIATED WITH BREAST AND COLORECTAL
CANCER
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OBJECTIVES: While many cost-effectiveness analysts devote
considerable effort to estimating the costs of the intervention,
most do not rigorously evaluate the medical cost implications of
the disease. Medical cost data is often old, inaccurate, or ignores
the cost implications over time. Using actuarial methods, we
develop rigorous estimates of the stream of medical costs asso-
ciated with breast and colorectal cancer. METHODS: Using a
350,000 annual member, 7-year longitudinal claims database, we
assessed the full stream of treatment costs following, and leading
up to, the diagnosis of cancer. To aid analysts so that they need
not add Markov states for each year of the disease in order to
capture these costs, we demonstrate how, using life contingen-
cies, this detailed cost stream can be represented as single present
value or annualized cost. RESULTS: Many cost-effectiveness
analysts do not incorporate the full stream of medical costs asso-
ciated with a disease. As a result, they typically underestimate
medical costs. For example, for preventive interventions, the
increased costs prior to formal diagnosis should be considered
because preventing the disease may avert some of these costs as
well. Further, because the medical costs are inevitably higher in
the earliest years of a disease, and because the use of discount-
ing effectively weights early costs more heavily than later costs,
the repeated use of a single average annual cost value will under-
estimate the present value of the stream of costs. CONCLU-
SIONS: The use of actuarial methods allows for improved
estimation of the stream of costs associated with cancer.
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